Compare
Cullinan Therapeutics, Inc. vs REGENXBIO Inc. vs Allogene Therapeutics, Inc. vs Vericel Corp
| Latest fiscal year | Cullinan Therapeutics, Inc. CGEMRevenue covers only part of its income (partial revenue) | REGENXBIO Inc. RGNX | Allogene Therapeutics, Inc. ALLO | Vericel Corp VCEL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $170.44M | $0 | $276.26M |
| Revenue growth (YoY) | n/a | +104.5% | -100.0% | +16.5% |
| Gross margin | n/a | n/a | n/a | 74.4% (computed) |
| Operating margin | n/a | -94.6% | n/a | 4.0% |
| Net margin | n/a | -113.8% | n/a | 6.0% |
| Net income | -$219.88M | -$193.88M | -$190.89M | $16.52M |
| EPS (Diluted) | n/a | -$3.76 | -$0.87 | $0.32 |
| Operating cash flow | -$175.75M | -$123.96M | -$149.25M | $51.91M |
| Free cash flow | -$175.80M | -$126.38M | -$149.63M | $24.75M |
| Cash & equivalents | $88.33M | $34.47M | $51.69M | $100.09M |
| Total assets | $448.37M | $453.03M | $415.90M | $487.97M |
| Total liabilities | $39.64M | $350.30M | $123.36M | $133.33M |
| Shareholders' equity | $408.73M | $102.73M | $292.54M | $354.64M |
| Return on year-end equity | -53.8% | -188.7% | -65.3% | 4.7% |
| Shares outstanding | 60.24M | 50.89M | 229.41M | 50.62M |
Revenue, most recent five fiscal years
| Fiscal year | Cullinan Therapeutics, Inc. | REGENXBIO Inc. | Allogene Therapeutics, Inc. | Vericel Corp |
|---|---|---|---|---|
| Latest | n/a | $170.44M Ended 2025-12-31 | $0 Ended 2025-12-31 | $276.26M Ended 2025-12-31 |
| 1 year earlier | n/a | $83.33M Ended 2024-12-31 | $22.0K Ended 2024-12-31 | $237.22M Ended 2024-12-31 |
| 2 years earlier | n/a | $90.24M Ended 2023-12-31 | $95.0K Ended 2023-12-31 | $197.52M Ended 2023-12-31 |
| 3 years earlier | n/a | $112.72M Ended 2022-12-31 | $156.0K Ended 2022-12-31 | $163.70M Ended 2022-12-31 |
| 4 years earlier | n/a | $470.35M Ended 2021-12-31 | $114.09M Ended 2021-12-31 | $153.07M Ended 2021-12-31 |